Editorial & Opinion
Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply.
| العنوان: | Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply. |
|---|---|
| المؤلفون: | Yiu TH; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Ko Y; School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.; Gastrointestinal and Liver Services Research Unit, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Pudipeddi A; Gastrointestinal and Liver Services Research Unit, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Natale P; School of Public Health, University of Sydney, Sydney, New South Wales, Australia.; Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari Aldo Moro, Bari, Italy.; Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Leong RW; Gastrointestinal and Liver Services Research Unit, Concord Repatriation General Hospital, Sydney, New South Wales, Australia. |
| المصدر: | Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Jul; Vol. 60 (1), pp. 103-104. Date of Electronic Publication: 2024 May 23. |
| نوع المنشور: | Letter; Comment |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987- |
| مواضيع طبية MeSH: | Crohn Disease*/drug therapy , Antibodies, Monoclonal*/therapeutic use, Humans ; United Arab Emirates ; Treatment Outcome |
| التعليقات: | Comment on: Aliment Pharmacol Ther. 2024 Jul;60(1):101-102. doi: 10.1111/apt.18049. (PMID: 38779929) |
| References: | Alahmad M, Quraishi MN, Khan SW, Omar NM, Malik AT. Letter: early real‐world evidence from The United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease. Aliment Pharmacol Ther. 2024;60:101–102. Yiu TH, Ko Y, Pudipeddi A, Natale P, Leong RW. Meta‐analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024;59(11):1312–1334. https://doi.org/10.1111/apt.18006. Zinger A, Choi D, Choi N, Cohen RD, Rubin DT. Risankizumab effectiveness and safety in Crohn's disease: real‐world data from a large tertiary center. Clin Gastroenterol Hepatol. 2023;S1542‐3565(23):00998‐9. Ferrante M, Panaccione R, Colombel JF, Dubinsky M, Hisamatsu T, Lindsay JO, et al. DOP53 long‐ term efficacy and safety of Risankizumab in patients with moderate to severe Crohn's disease up to 3 years of treatment: results from the FORTIFY open‐label long‐term extension. J Crohns Colitis. 2024;18(Supplement_1):i168–i170. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double‐blind, placebo‐controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet Lond Engl. 2022;399(10340):2031–2046. Peyrin‐Biroulet L, Bossuyt P, Regueiro M, Schreiber S, Gecse K, Irving P, et al. DOP10 Risankizumab versus Ustekinumab for the achievement of endoscopic outcomes in patients with moderate‐to‐ severe Crohn's disease: results from the phase 3b SEQUENCE trial. J Crohns Colitis. 2024;18(Supplement_1):i90–i91. |
| المشرفين على المادة: | 90ZX3Q3FR7 (risankizumab) 0 (Antibodies, Monoclonal) |
| تواريخ الأحداث: | Date Created: 20240523 Date Completed: 20240611 Latest Revision: 20240710 |
| رمز التحديث: | 20240710 |
| DOI: | 10.1111/apt.18057 |
| PMID: | 38779926 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2036 |
|---|---|
| DOI: | 10.1111/apt.18057 |